학술논문
미국의 위해성 평가 및 완화전략 공유시스템의 현황 및 시사점
이용수 29
- 영문명
- Current Status and Implications of the Shared System Risk Evaluation and Mitigation Strategy in the United States
- 발행기관
- 한국보건사회약료경영학회
- 저자명
- 간행물 정보
- 『한국보건사회약료경영학회지』제10권 제1호, 37~42쪽, 전체 6쪽
- 주제분류
- 의약학 > 기타의약학
- 파일형태
- 발행일자
- 2022.05.31
4,000원
구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.
국문 초록
영문 초록
In the United States, the Risk Evaluation and Mitigation Strategy (REMS) has been implemented since 2007, and generic products of original drugs under REMS are also subject to REMS. South Korea has adopted a Risk Management Plan (RMP) to ensure drug safety throughout the drug’s product cycle in 2015. This paper reviews the current status of a Shared System (SS) REMS in the United States and the SS REMS of isotretinoin (iPLEDGE program) to understand its implications for Korea's RMP system. In the United States, generic manufacturers can either individually implement REMS or collaborate with original manufacturers. SS REMS benefits the shareholders by reducing the work burden of participating companies, sharing development costs, and maintaining consistency of risk management in clinical settings. The iPLEDGE program is the oldest and most representative SS REMS. It was developed to prevent potential fetal exposure to isotretinoin. A central, systematic risk management website inspects isotretinoin distribution, prescribing, dispensing, and utilization. For example, prescribing isotretinoin is permitted when the results of pregnancy lab tests and contraceptive methods are entered into the website. Since more generic drugs are expected to enter the market in Korea, the SS of RMP can be a systematic approach to maintain a coherent risk mitigation strategy and reduce the operational burden of manufacturers.
목차
서 론
본 론
고찰 및 결론
참고문헌
해당간행물 수록 논문
참고문헌
교보eBook 첫 방문을 환영 합니다!
신규가입 혜택 지급이 완료 되었습니다.
바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!